Tuberculosis Care in Indonesia: A Financial Analysis of Strategic Purchasing in Medan

By Charmi Patel

June 24, 2024

Introduction

Tuberculosis (TB) remains a significant public health challenge globally, particularly in low- and middle-income countries. Effective TB control requires not only robust clinical interventions but also efficient health financing mechanisms. Traditional payment models, such as fixed capitation payments, often fall short in addressing the complexities and costs associated with TB diagnosis and treatment. Despite 88.6% National Health Insurance (NHI) scheme (Jaminan Kesehatan Nasional) coverage, 38.4% of TB-affected households face catastrophic costs, with out-of-pocket spending exceeding 20% of income due to high TB service expenses, over-referrals to hospitals, and gaps in coverage.

Financial Impact Analysis

Experts developed a budget impact model to assess the cost-effectiveness of strategic purchasing in improving TB reporting and treatment success rates. The model predicts a substantial increase in TB reporting by 63% and successful treatments by 64% under strategic purchasing. Consequently, this would lead to a 60% rise in total spending on TB care. Yet, the cost per patient is expected to drop by 3% with care shifting to cost-effective primary healthcare settings, reflecting increased diagnostic costs.

Results and Implications

The analysis indicates that while strategic purchasing may initially raise overall spending on TB care, it can significantly enhance TB care in Indonesia. By identifying more cases, treating them more effectively, and consequently reducing the cost per patient, strategic purchasing offers a promising avenue for improving TB care delivery. The model projects a 64% surge in TB case notifications and a 64.5% boost in successful treatment under strategic purchasing, thereby leading to advancement of cost-effective care and improving health outcomes.

Table 2: Comparison between the current and proposed scenarios, showing the impact on vertical referrals, confirmed TB cases notified, and TB patients completing treatment.
Table 1: Comparison between the current and proposed scenarios, showing the impact on vertical referrals, confirmed TB cases notified, and TB patients completing treatment.

 

Figure 3: The cost-effectiveness of the proposed strategic health purchasing approach under different scenarios of treatment success rates.
Figure 1: The cost-effectiveness of the proposed strategic health purchasing approach under different scenarios of treatment success rates.

 

Table 5: This table breaks down the costs for different payers (NHI, central and local government, Global Fund, and out-of-pocket) under the current and proposed scenarios, highlighting the financial implications of the new approach.
Table 2: This table breaks down the costs for different payers (NHI, central and local government, Global Fund, and out-of-pocket) under the current and proposed scenarios, highlighting the financial implications of the new approach.

Conclusion

In conclusion, strategic purchasing presents a viable strategy to address Indonesia’s TB burden effectively. By incentivising primary healthcare providers and promoting efficient care, this approach transforms TB accessibility, treatment effectiveness, and cost-efficiency. Furthermore, the financial analysis emphasises strategic purchasing benefits, stressing aligning incentives with quality care for sustainable TB control strategies.

Reference url

Recent Posts

Ravulizumab aHUS Reimbursement Reassessment: Navigating New Evidence and Treatment Impact

By HEOR Staff Writer

September 15, 2025

Zorginstituut Nederland is reassessing ravulizumab aHUS reimbursement for treating atypical hemolytic uremic syndrome (aHUS) - a rare immune system disorder. The drug was previously rejected in 2021 due to insufficient scientific evidence. The medication is administered via infusion and targets p...
New Federal Actions to Combat Misleading Prescription Drug Ads in 2025

By João L. Carapinha

September 11, 2025

Misleading prescription drug ads have become a pressing concern in the United States, prompting decisive federal action. What are the new measures targeting deceptive pharmaceutical advertising, and how will these changes affect public health and healthcare costs? In September 2025, a
Medicare ACO Outcomes: Balancing Surgical Benefits and Costs Under the TEAM Model

By João L. Carapinha

September 9, 2025

Medicare ACO outcomes are a major focus for clinicians, policymakers, and researchers seeking to understand how Accountable Care Organization (ACO) assignment influences patient results and healthcare costs after surgery. Are ACOs improving quality and saving money for Medicare patients undergoin...